Granules India Ltd. announced a strong financial performance for Q3FY26. Revenue from operations increased by 22% YoY to INR 13,879 Mn. EBITDA saw a 34% YoY increase, reaching INR 3,081 Mn, while PAT grew by 28% YoY to INR 1,502 Mn. The results reflect the company’s strategic growth initiatives and strong performance in the Finished Dosages segment.
Financial Highlights for Q3FY26
Granules India Ltd. reported its financial results for the quarter ended December 31, 2025, showcasing significant growth across key metrics:
- Revenue from Operations:INR 13,879 Mn, a 22% increase compared to Q3FY25.
- EBITDA:INR 3,081 Mn, representing a substantial 34% growth YoY.
- PBT:INR 2,022 Mn, up by 32% compared to the previous year.
- PAT:INR 1,502 Mn, reflecting a strong 28% increase YoY.
Segment Performance
The growth in revenue from operations was primarily driven by the Finished Dosages (FD) segment, with strong performance in North America and Europe. The contribution of different segments to the total revenue is as follows:
- Finished Dosages (FD): 76%
- Active Pharmaceutical Ingredients (API): 11%
- Pharmaceutical Formulation Intermediates (PFI): 11%
- Peptides/ CDMO: 2%
Other Key Metrics
Other important financial metrics for the quarter include:
- ROCE: stood at 16.8% (Post Acquisition of Senn Chemicals AG).
- Net Debt:INR 10,151 Mn
- Net Debt to EBITDA:0.91x
Source: BSE
